Drobnjak M, Cote R, Saad A, Drudis T, Fuks Z, Cordoncardo C
UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033. IMPATH LABS,NEW YORK,NY 10021.
Int J Oncol. 1993 Feb;2(2):173-8. doi: 10.3892/ijo.2.2.173.
Expression of Rb and mutant p53 nuclear phosphoproteins was analyzed immunohistochemically in 69 breast cancer patients. Results were correlated with hormone receptor ( ER and PR ) and lymph node ( LN ) status. There was a significant association between the immunohistochemical evidence of p53 and/or Rb alterations and loss of hormone receptor expression. Mutations in p53 and/or low level Rb expression were not associated with the presence of axillary lymph node metastases. However, in patients with hormone receptor positive tumors, there was statistically significant correlation between altered expression of p53 and/or Rb and the presence of LN metastases. These results indicate that: (i) loss of steroid hormone receptor expression (and thus loss of hormonal growth control) is accompanied by somatic inactivation of the p53 or Rb tumor suppressor genes; and (ii) in tumors that remain under hormonal growth regulation inactivation of p53 and/or Rb may play a role in tumor progression.
对69例乳腺癌患者进行免疫组织化学分析,检测Rb和突变型p53核磷蛋白的表达情况。结果与激素受体(雌激素受体和孕激素受体)及淋巴结状态相关。p53和/或Rb改变的免疫组织化学证据与激素受体表达缺失之间存在显著关联。p53突变和/或低水平Rb表达与腋窝淋巴结转移的存在无关。然而,在激素受体阳性肿瘤患者中,p53和/或Rb表达改变与淋巴结转移的存在之间存在统计学显著相关性。这些结果表明:(i)类固醇激素受体表达缺失(从而激素生长控制缺失)伴随着p53或Rb肿瘤抑制基因的体细胞失活;(ii)在仍受激素生长调节的肿瘤中,p53和/或Rb失活可能在肿瘤进展中起作用。